Welcome - Home - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Viewing report Order by Fax Printer Friendly PDF Brochure Send to Friend Enquire before Buying Electronic (PDF) Site License Enterprisewide Advanced Life Sciences Cethromycin - Phase III Success Should Allow Me-too Market Entry and Above-consensus Growth Datamonitor, Sep 2006, Pages: 17   Description     Table of Contents     Companies Mentioned        Enquire before Buying    Send to a Friend   Traditionally, the treatment of respiratory infections has largely involved antibiotics from the macrolide class. Advanced Life Sciences cethromycin, along with Sanofi-Aventis Ketek, is a ketolide, a second-generation class of macrolides with activity against bacterial strains resistant to macrolides. Data from two Phase III trials in community-acquired pneumonia are expected in early 2007. Scope of this title: - Analyzes the potential for FDA approval and the market outlook for Advanced Life Sciences cethromycin - We interviewed six infectious disease specialists and high-prescribing primary care physicians in the course of research Highlights of this title: - While there is some risk, dosing improvements over previous failed trials give cethromycin a good chance of yielding positive results in ongoing Phase III trials. - We expect slow, steady erosion in market share of the macrolide class by the ketolides, driven by concerns over resistant strains of pathogens, but tempered by the established position of Pfizers leading macrolide, Zithromax, and the price discounts offered by its generic form. - Recent concern over liver toxicity associated with Sanofi-Aventis Ketek, is likely to make physicians wary of cethromycin as well before its side effect profile is better known. Reasons to order your copy: - Understand the commercial potential for Advanced Life Sciences cethromycin, through in-depth analysis based on interviews with leading experts - Anticipate likely changes in the future market dynamics for antibacterial agents if cethromycin were to be approved Customers who bought this item also bought India: Pharmaceutical and biotechnology opportunities Global Pharmaceuticals, Biotechnology & Life Sciences Global Pharmaceutical Launches: Marketing Budgets and Staffing (Phase 3 to Post-Launch) Life Sciences Industry: Quarterly Deal Review--Fourth Quarter 2004 Gilead Sciences Inc Deals Briefing BioMed Outsourcing Report - The Role of Incubators in Supporting the Biopharmaceutical Outsourcing Sector Cancer Drug Discoveries: What the Future Holds Advanced Life Sciences Holdings, Inc.-Financial Company Report

		Top of page

All rights reserved. � Copyright 2008 Research and Markets    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster